Evotaz ® (atazanavir/cobicistat) – Expanded indication
July 31, 2020 - The FDA approved Bristol-Myers Squibb’s Evotaz (atazanavir/cobicistat), in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV)-1 infection in adults and pediatric patients weighing at least 35 kg.
Top